Evidence Hub

C5 inhibition with eculizumab prevents thrombotic microangiopathy in a case series of pig-to-human kidney xenotransplantation

Maggie Jones-Carr, Huma Fatima, Vineeta Kumar, D. Anderson, Julie G Houp, Jackson Perry, Gavin A. Baker, Leigh McManus et al.

Journal of Clinical Investigation, 2024

36 citations

Abstract

To the Editor: Although studies of porcine kidney xenotransplantation in nonhuman primates (NHPs) and brain-dead humans have improved our understanding of anti-xenograft immune responses (1–3), the optimal immunosuppression regimen for living human recipients is unknown (3). Prior NHP studies suggest that complement plays an important role in immune-mediated injury of xenografts (4), but the benefits of pharmacologic complement inhibition in human xenograft recipients have yet to be established. Here, we report the histologic outcomes of a series of brain-dead human recipients of a porcine kidney xenotransplant using exclusively FDA-approved medications, with and without anti-C5 monoclonal antibody. Three male decedents, aged 57, 65, and 53 years, respectively, underwent bilateral native nephrectomies, followed by crossmatch-compatible xenotransplantation (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI175996DS1) with 10 gene-edited (10GE) pig kidneys that expressed 2 human transgenes responsible for classical complement cascade inhibition (CD46 and DAF) (2) with standard immunosuppression (Supplemental Methods). There was no evidence of hyperacute rejection in any decedent. Decedents 2 and 3 received anti-C5 monoclonal antibody therapy (eculizumab) 24 hours prior to (1,200 mg) and 24 hours after (900 mg) xenotransplantation. Decedent 1 native kidney and 10GE porcine donor kidney biopsies were histologically normal…

How strong is the evidence?

Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free